Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness

Sleep Medicine

Volumn 9, Issue 5, 2008, Pages 506-510

  Bart Sangal, R ^a   Sangal, JoAnne M ^a   Thorp, Krista ^a  

^a Sleep Disorders Institute   (United States)

Author keywords

Atomoxetine; ESS; Norepinephrine reuptake inhibitor; Obstructive sleep apnea; Respiratory disturbance index; Sleepiness

Indexed keywords

ATOMOXETINE; OXYGEN;

ADULT; APNEA; AROUSAL; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EPWORTH SLEEPINESS SCALE; FEMALE; HEART PALPITATION; HUMAN; INSOMNIA; MALE; NAUSEA; NOSE CONGESTION; OUTCOME ASSESSMENT; OXYGEN SATURATION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP INDUCTION; SLEEP PATTERN; SLEEP TIME; SOMNOLENCE; SORE THROAT; TREATMENT DURATION; URINARY FREQUENCY; WAKEFULNESS; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AROUSAL; ATTENTION; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; PROPYLAMINES; SLEEP APNEA, OBSTRUCTIVE; SLEEP STAGES; WAKEFULNESS; YOUNG ADULT;

EID: 45249113042     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2007.07.013     Document Type: Article

References (23)

1. Young T., Palta M., Dempsey J., Skatrud J., Weber S., and Badr S. The occurrence of sleep-disordered breathing in middle-aged adults. N Engl J Med 338 (1993) 1230-1235
2. Redline S., Kapur V.K., Sanders M.H., Quan S.F., Gottlieb D.J., Rapoport D.M., et al. Effects of varying approaches for identifying respiratory disturbances on sleep apnea assessment. Am J Respir Crit Care Med 161 (2000) 369-374
3. Manser R.L., Rochford P., Pierce R.J., Byrnes G.B., and Campbell D.A. Impact of different criteria for defining hypopneas in the apnea-hypopnea index. Chest 120 (2001) 909-914
4. Orth M., Kotterba S., Walther J.W., Rasche K., Schultze-Werninghaus G., and Duchna H.W. Long-term compliance of CPAP therapy - update, predictors and interventions. Pneumologie 60 (2006) 480-484
5. Rose E., Staats R., Schulte-Monting J., Ridder G.J., and Jonas I.E. Long term compliance with an oral protrusive appliance in patients with obstructive sleep apnoea. Dtsch Med Wochenschr 127 (2002) 1245-1249
6. Brownell L.G., West P., Sweatman P., Acres J.C., and Kryger M.H. Protriptyline in obstructive sleep apnea: a double-blind trial. New Engl J Med 307 (1982) 1037-1042
7. Brownell L.G., Perez-Padilla R., West P., and Kryger M.H. The role of protriptyline in obstructive sleep apnea. Bull Eur Physiopath Resp 19 (1983) 621-624
8. Smith P.L., Haponik E.F., Allen R.P., and Bleecker E.R. The effects of protriptyline in sleep-disordered breathing. Am Rev Respir Dis 127 (1983) 8-13
9. Hanzel D.A., Proia N.G., and Hudgel D.W. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 100 (1991) 416-421
10. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F.R., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) e83
11. Spencer T., Heiligenstein J.H., Biederman J., Faries D.E., Kratochvil C.J., Conners C.K., et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63 (2002) 1140-1147
12. Michelson D., Allen A.J., Busner J., Casat C., Dunn D., Kratochvil C., et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159 (2002) 1896-1901
13. Kelsey D.K., Sumner C.R., Casat C.D., Coury D.L., Quintana H., Saylor K.E., et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114 (2004) e1-e8
14. Sauer J.M., Ring B.J., and Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44 (2005) 571-590
15. Sangal R.B., Owens J., Allen A.J., Sutton V., Schuh K., and Kelsey D. Effects of Atomoxetine and Methylphenidate on sleep of children with ADHD. Sleep 29 (2006) 1573-1585
16. Andrews G.D., and Lavin A. Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology 31 (2006) 594-601
17. Herwig U., Brauer K., Connemann B., Spitzer M., and Schonfeldt-Lecuona C. Intracortical excitability is modulated by a norepinephrine-reuptake inhibitor as measured with paired-pulse transcranial magnetic stimulation. Psychopharmacology (Berl) 164 (2002) 228-232
18. Plewnia C., Hoppe J., Hiemke C., Bartels M., Cohen L.G., and Gerloff C. Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine. Neurosci Lett 27 (2002) 231-234
19. Robol E., Fiaschi A., and Manganotti P. Effects of citalopram on the excitability of the human motor cortex: a paired magnetic stimulation study. J Neurol Sci 221 (2004) 41-46
20. Scates A.C., and Doraiswamy P.M. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 34 (2000) 1302-1312
21. Yevgenia Gelfin M.D., Malka Gorfine M.A., and Bernard Lerer M.D. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psychiatry 155 (1998) 290-292
22. Pack A.I., Black J.E., Schwartz J.R., and Matheson J.K. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 164 (2001) 1675-1681
23. Schwartz J.R., Hirshkowitz M., Erman M.K., and Scmhidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 124 (2003) 1292-1299